摘要
目的观察以羟基喜树碱(HCPT)注射液为主的联合方案治疗难治性恶性淋巴瘤的疗效.方法HCPT10 mg/次,静脉滴注,2 h,联合Ara-C或VP16或PYM治疗难治性恶性淋巴瘤18例,其中非霍奇金淋巴瘤15例,霍奇金淋巴瘤3例.结果CR1例,PR9例,总有效率55.5%,无进展生存1.5～10个月.该方案毒副作用轻,患者耐受性良好.结论羟基喜树碱联合方案治疗难治性恶性淋巴瘤有一定疗效,值得进一步观察和总结.
Objective To observe the effect of hydroxy- camptothecine(HCPT)- based combination regimen in the treatment of patients with refractory malignant lymphoma. Methods 18 cases with refractory and replased lymphoma(15 NHL, 3 HL)were treated with HCPT 10 mg/d, ivgtt, maintain 2 h, qnd, for 4~ 5 times, combined with VP16 or Ara- C or PYM. Results The overall response rate was 55.5 %(10/18), with 1 complete remission(CR) and 9 partial remission(PR). Mediam duration of responses was 4.5 months(1.5~10 months). All patients were tolerated with this protocal and no severe side reaction was observed. Conclusions The protocal is activity as salvage therapy for relapsed and refractory lymphoma patients and is worthwhile to be further investigated and used in clinic.
出处
《白血病．淋巴瘤》
CAS
2005年第3期151-152,共2页
Journal of Leukemia & Lymphoma
关键词
恶性淋巴瘤
难治性
羟基喜树碱
Hydroxy- camptothecine
Malignant lymphoma
Refractory
